More about GeNeuro’s lead product

GeNeuro has strong expertise in the development of monoclonal antibodies, which are proteins that can bind to specific targets. Monoclonal antibodies can be designed to recognize and neutralize molecules involved in disease processes and they are produced through genetic engineering. GeNeuro’s lead therapeutic product is a humanized monoclonal antibody, called GNbAC1, which targets MSRV-Env.